Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MDxHealth Eyes 2016 Liquid Biopsy Prostate Cancer Test Launch With NovioGendix Buy

This article was originally published in Clinica

Executive Summary

Belgian epigenetics specialist MDxHealth is planning to launch in the US and Europe next year a new noninvasive test to guide doctors in determining which patients are at low or high risk of prostate cancer. The test, which will help reduce unnecessary prostate biopsy procedures and their associated costs and complications, is based on technology which MDxHealth will gain through the agreed acquisition of NovioGendix, a spinout of Radboud University Medical Center in the Netherlands.


Related Content

MDxHealth Gears Up For Major EU Growth





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts